JPS631290B2 - - Google Patents
Info
- Publication number
- JPS631290B2 JPS631290B2 JP52075943A JP7594377A JPS631290B2 JP S631290 B2 JPS631290 B2 JP S631290B2 JP 52075943 A JP52075943 A JP 52075943A JP 7594377 A JP7594377 A JP 7594377A JP S631290 B2 JPS631290 B2 JP S631290B2
- Authority
- JP
- Japan
- Prior art keywords
- urokinase
- molecular weight
- molecular
- blood
- fibrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 71
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 71
- 229960005356 urokinase Drugs 0.000 claims description 68
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000000502 dialysis Methods 0.000 claims description 6
- 238000011033 desalting Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 description 25
- 230000000694 effects Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 230000002537 thrombolytic effect Effects 0.000 description 14
- 102000009123 Fibrin Human genes 0.000 description 12
- 108010073385 Fibrin Proteins 0.000 description 12
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 12
- 229950003499 fibrin Drugs 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000003146 anticoagulant agent Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000003480 fibrinolytic effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940106780 human fibrinogen Drugs 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000011547 Bouin solution Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000013365 molecular weight analysis method Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003766 thrombin (human) Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7594377A JPS5411219A (en) | 1977-06-25 | 1977-06-25 | Thrombolytic agent and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7594377A JPS5411219A (en) | 1977-06-25 | 1977-06-25 | Thrombolytic agent and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5411219A JPS5411219A (en) | 1979-01-27 |
| JPS631290B2 true JPS631290B2 (fr) | 1988-01-12 |
Family
ID=13590808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7594377A Granted JPS5411219A (en) | 1977-06-25 | 1977-06-25 | Thrombolytic agent and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5411219A (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02188898A (ja) * | 1989-01-17 | 1990-07-24 | Sanyo Electric Co Ltd | カップ式飲料販売機 |
| KR100586781B1 (ko) * | 1998-06-11 | 2006-06-08 | 혼다 기켄 고교 가부시키가이샤 | 유체 필터 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4370417A (en) * | 1980-04-03 | 1983-01-25 | Abbott Laboratories | Recombinant deoxyribonucleic acid which codes for plasminogen activator |
| GB8400653D0 (en) * | 1984-01-11 | 1984-02-15 | Beecham Group Plc | Conjugates |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4966885A (fr) * | 1972-10-30 | 1974-06-28 | ||
| JPS50123869A (fr) * | 1974-03-13 | 1975-09-29 | ||
| JPS50160473A (fr) * | 1974-06-21 | 1975-12-25 | ||
| JPS53130485A (en) * | 1977-04-12 | 1978-11-14 | Choay Sa | Separating method of urokinase and medicin containg urokinase as useful component |
-
1977
- 1977-06-25 JP JP7594377A patent/JPS5411219A/ja active Granted
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4966885A (fr) * | 1972-10-30 | 1974-06-28 | ||
| JPS50123869A (fr) * | 1974-03-13 | 1975-09-29 | ||
| JPS50160473A (fr) * | 1974-06-21 | 1975-12-25 | ||
| JPS53130485A (en) * | 1977-04-12 | 1978-11-14 | Choay Sa | Separating method of urokinase and medicin containg urokinase as useful component |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02188898A (ja) * | 1989-01-17 | 1990-07-24 | Sanyo Electric Co Ltd | カップ式飲料販売機 |
| KR100586781B1 (ko) * | 1998-06-11 | 2006-06-08 | 혼다 기켄 고교 가부시키가이샤 | 유체 필터 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5411219A (en) | 1979-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4297344A (en) | Blood coagulation factors and process for their manufacture | |
| Regoeczi et al. | In vivo effects of Agkistrodon rhodostoma venom: studies with fibrinogen-131I. | |
| DE69634373T2 (de) | Verfahren zur Herstellung von Konjugaten vom Faktor VIII mit einem biologisch verträglichen Polymer | |
| US4743680A (en) | Method for purifying antihemophilic factor | |
| US4692435A (en) | Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation | |
| NO160114B (no) | Blanding for bruk ved ekstern paavisning og lokalisering av blodpropp. | |
| Sherman et al. | In vitro formation and in vivo clearance of fibrinogen: fibrin complexes | |
| JPH07503454A (ja) | プラズミンによる線維素溶解および線維素原溶解治療 | |
| JPH07501517A (ja) | 局所用フィブリノーゲン複合体 | |
| JPH0323528B2 (fr) | ||
| US3998947A (en) | Process for obtaining a plasminogen activator | |
| JPS61243024A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
| NL8601354A (nl) | Nieuwe samenstelling. | |
| JPS59137417A (ja) | 人尿由来コロニ−形成刺激因子及びカリクレインの製造法 | |
| US4314994A (en) | Process for obtaining a plasminogen activator | |
| Sherman et al. | In vivo transformation between fibrinogens of varying ethanol solubilities: a pathway of fibrinogen catabolism | |
| JPH02504587A (ja) | ７ａ因子に富む画分の製造方法及び医薬としてのその用途 | |
| JPH0567278B2 (fr) | ||
| US4029767A (en) | Pharmaceutical compositions of stable urokinase-heparin complexes and methods for use thereof | |
| US4286063A (en) | Method for producing thrombolytic preparation | |
| JPS631290B2 (fr) | ||
| Budzynski et al. | Determination of human fibrinopeptide A by radioimmunoassay in purified systems and in the blood | |
| Silberman et al. | Effects of ancrod (Arvin) in mice: studies of plasma fibrinogen and fibrinolytic activity | |
| EP0099126B1 (fr) | Composition thrombolytique | |
| Kim et al. | Immobilization of urokinase on agarose matrices |